The use of rapid lateral flow antigen testing (LFT) for SARS-CoV-2 has been questioned1, 2, 3 with uncorroborated4 reports of poor LFT sensitivity. The debate surrounding the use of the Innova Lateral Flow SARS-CoV-2 Antigen Test in the UK risks confusing policy makers internationally and potentially stalling deployment of LFTs in other countries.5 As scientists and health professionals evaluating some… Continue reading The Lancet: Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic, and asymptomatic infections, the reopening of societies and the control of virus spread will be facilitated by robust population screening, for which virus testing will often be central. After infection, individuals undergo a period of incubation during… Continue reading Science: Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening
Many types of tests are available for COVID-19 for clinical and public health use (see the figure). Testing can be performed in a central laboratory, at the point of care (POC), or in the community at the workplace, school, or home. COVID-19 testing begins with specimen collection. For medical use, a nasopharyngeal swab collected by… Continue reading Science: COVID-19 testing: One size does not fit all